Inventor Search

=> d ibib abs hitstr l6 1-1

L6 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:76264 HCAPLUS
DOCUMENT NUMBER: 142:162638
TITLE: Enema formulations containing thiazoles for treating inflammatory bowel disease
INVENTOR(S): Maeda, Takashi; Nagamoto, Hisashi; Chihiro, Masatoshi
PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005007160	A1	20050127	WO 2004-JP10546		20040716
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004257527	A1	20050127	AU 2004-257527		20040716
CA 2531343	AA	20050127	CA 2004-2531343		20040716
EP 1646384	A1	20060419	EP 2004-786033		20040716
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
JP 2005047915	A2	20050224	JP 2004-212030		20040720
PRIORITY APPLN. INFO.:			JP 2003-275955	A	20030717
			WO 2004-JP10546	W	20040716

OTHER SOURCE(S): MARPAT 142:162638

AB The object of this invention is to provide an enema formulation for treating inflammatory bowel diseases. The enema formulation comprises thiazole derivs. Thus, a formulation contained (6-[2-(3,4-diethoxyphenyl)thiazol-4-yl]pyridine-2-carboxylic acid) 1.0, tri(hydroxymethyl)aminomethane 1.2, NaOH1.2, and sodium CM-cellulose 15 mg/mL. HCl qs and water qs.

IT 288-47-1D, Thiazole, derivs. 145739-56-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(enema formulations for treating inflammatory bowel disease)

RN 288-47-1 HCAPLUS
CN Thiazole (6CI, 8CI, 9CI) (CA INDEX NAME)

RN 145739-56-6 HCAPLUS

CN 2-Pyridinecarboxylic acid, 6-[2-(3,4-diethoxyphenyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his ful

     (FILE 'HOME' ENTERED AT 16:35:50 ON 18 JUN 2006)

     FILE 'HCAPLUS' ENTERED AT 16:35:58 ON 18 JUN 2006
                E MAEDA TAKASHI/AU
L1           396 SEA ABB=ON  "MAEDA TAKASHI"/AU
                E NAGAMOTO HISASHI/AU
L2            11 SEA ABB=ON  "NAGAMOTO HISASHI"/AU
                E CHIHIRO MASATOSHI/AU
L3            28 SEA ABB=ON  ("CHIHIRO MASATOSHI"/AU OR "CHIHIRO MASOTOSHI"/AU)
L4             1 SEA ABB=ON  L1 AND L2 AND L3
                SELECT RN L4 1

     FILE 'REGISTRY' ENTERED AT 16:37:00 ON 18 JUN 2006
L5             2 SEA ABB=ON  (145739-56-6/BI OR 288-47-1/BI)

     FILE 'HCAPLUS' ENTERED AT 16:37:05 ON 18 JUN 2006
L6             1 SEA ABB=ON  L4 AND L5
L7               ANALYZE L6 1-1 CT :       3 TERMS

     FILE 'REGISTRY' ENTERED AT 16:39:20 ON 18 JUN 2006
L8               STR
L9             0 SEA SSS SAM L8
L10            0 SEA SSS FUL L8
L11              STR L8
L12            0 SEA SSS SAM L11
L13            1 SEA SSS FUL L11

     FILE 'HCAPLUS' ENTERED AT 16:54:32 ON 18 JUN 2006
L14            1 SEA ABB=ON  L13

     FILE 'REGISTRY' ENTERED AT 16:55:46 ON 18 JUN 2006
L15              STR L11
L16            1 SEA SSS SAM L15
L17              STR L15
L18            7 SEA SSS SAM L17
L19              STR L17
L20            0 SEA SSS SAM L19
L21            4 SEA SSS FUL L19

     FILE 'HCAPLUS' ENTERED AT 17:02:18 ON 18 JUN 2006
L22            3 SEA ABB=ON  L21

     FILE 'REGISTRY' ENTERED AT 17:03:16 ON 18 JUN 2006
L23              STR L19
L24            7 SEA SSS SAM L23
L25          218 SEA SSS FUL L23

     FILE 'HCAPLUS' ENTERED AT 17:03:51 ON 18 JUN 2006
L26           42 SEA ABB=ON  L25
L27            4 SEA ABB=ON  L26 AND (?INFLAM?(W)?BOWEL? OR IFB)
L28            1 SEA ABB=ON  L27 AND ?ENEMA?
L29            4 SEA ABB=ON  (L27 OR L28)
L30            1 SEA ABB=ON  L29 AND (PRD<20030717 OR PD<20030717)

     FILE 'USPATFULL' ENTERED AT 17:14:41 ON 18 JUN 2006
L31            7 SEA ABB=ON  L29 AND (PRD<20030717 OR PD<20030717)
```

1 cit from CA Plus

7 cits from USPatFull

FILE HOME

FILE HCAPLUS

FILE COVERS 1907 - 18 Jun 2006 VOL 144 ISS 26
FILE LAST UPDATED: 16 Jun 2006 (20060616/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 JUN 2006 HIGHEST RN 888069-20-3
DICTIONARY FILE UPDATES: 16 JUN 2006 HIGHEST RN 888069-20-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*************************************************************
*                                                           *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                           *
*************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 15 Jun 2006 (20060615/PD)
FILE LAST UPDATED: 15 Jun 2006 (20060615/ED)
HIGHEST GRANTED PATENT NUMBER: US7062785
HIGHEST APPLICATION PUBLICATION NUMBER: US2006130207

CA INDEXING IS CURRENT THROUGH 15 Jun 2006 (20060615/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 15 Jun 2006 (20060615/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2006

```
=> d que stat l30
L23             STR
```



```
VPA 1-21/22/23 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT   IS LOC  AT  15
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  19

STEREO ATTRIBUTES: NONE
L25         218 SEA FILE=REGISTRY SSS FUL L23
L26          42 SEA FILE=HCAPLUS ABB=ON  L25
L27           4 SEA FILE=HCAPLUS ABB=ON  L26 AND (?INFLAM?(W)?BOWEL? OR IFB)
L28           1 SEA FILE=HCAPLUS ABB=ON  L27 AND ?ENEMA?
L29           4 SEA FILE=HCAPLUS ABB=ON  (L27 OR L28)
L30           1 SEA FILE=HCAPLUS ABB=ON  L29 AND (PRD<20030717 OR PD<20030717)

=> d ibib abs hitstr l30 1-1

L30  ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2001:93226  HCAPLUS
DOCUMENT NUMBER:          134:290370
TITLE:                    OPC-compounds prevent oxidant-induced carbonylation
                          and depolymerization of the F-actin cytoskeleton and
                          intestinal barrier hyperpermeability
AUTHOR(S):                Banan, A.; Fitzpatrick, L.; Zhang, Y.; Keshavarzian,
                          A.
CORPORATE SOURCE:         Departments of Internal Medicine (Division of
                          Digestive Diseases), Pharmacology, and Molecular
                          Biophysics and Physiology, Rush University Medical
                          Center, Chicago, IL, USA
SOURCE:                   Free Radical Biology & Medicine (2001),
                          30(3), 287-298
                          CODEN: FRBMEH; ISSN: 0891-5849
PUBLISHER:                Elsevier Science Inc.
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
AB   Rebamipide (OPC-12759), a quinolone derivative, and OPC-6535, a
     thiazol-carboxylic acid derivative, are compds. with ability to protect
     gastrointestinal (GI) mucosal integrity against reactive oxygen
     metabolites (ROM). The underlying mechanism of OPC-mediated protection
     remains poorly understood. It is now established that ROM can injure the
     mucosa by disruption of the cytoskeletal network, a key component of
     mucosal barrier integrity. We, therefore, investigated whether OPC
     compds. prevent the oxidation, disassembly, and instability of the
     cytoskeletal protein actin and, in turn, protect intestinal barrier
     function against ROM. Human intestinal (Caco-2) cell monolayers were
     pretreated with OPC (-12759 or -6535) prior to incubation with ROM (H2O2
```

or HOCl). Effects on cell integrity (ethidium homodimer-1), epithelial barrier function (fluorescein sulfonic acid clearance), and actin cytoskeletal integrity (high-resolution laser confocal) were then determined Cells were also processed for quant. immunoblotting of G- and F-actin to measure oxidation (carbonylation) and disassembly of actin. In monolayers exposed to ROM, preincubation with OPC compds. prevented actin oxidation, decreased depolymd. G-actin, and enhanced the stable F-actin. Concomitantly, OPC agents abolished both actin cytoskeletal disruption and monolayer barrier dysfunction. Data suggest for the first time that OPC drugs prevent oxidation of actin and lead to the protection of actin cytoskeleton and intestinal barrier integrity against oxidant insult. Accordingly, these compds. may be used as novel therapeutic agents for the treatment of a variety of oxidative inflammatory intestinal disorders with an abnormal mucosal barrier such as inflammatory bowel disease.

IT 145739-56-6, OPC-6535
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mechanism of gastrointestinal protection by rebamipide and OPC-6535)

RN 145739-56-6 HCAPLUS

CN 2-Pyridinecarboxylic acid, 6-[2-(3,4-diethoxyphenyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d que stat l31
L23             STR
```




```
VPA 1-21/22/23 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT   IS LOC  AT  15
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  19

STEREO ATTRIBUTES: NONE
L25         218 SEA FILE=REGISTRY SSS FUL L23
L26          42 SEA FILE=HCAPLUS ABB=ON  L25
L27           4 SEA FILE=HCAPLUS ABB=ON  L26 AND (?INFLAM?(W)?BOWEL? OR IFB)
L28           1 SEA FILE=HCAPLUS ABB=ON  L27 AND ?ENEMA?
L29           4 SEA FILE=HCAPLUS ABB=ON  (L27 OR L28)
L31           7 SEA FILE=USPATFULL ABB=ON  L29 AND (PRD<20030717 OR PD<20030717
                )


=> d ibib abs hitstr l31 1-7

L31  ANSWER 1 OF 7  USPATFULL on STN
ACCESSION NUMBER:       2004:294735  USPATFULL
TITLE:                  Compounds and methods of uses
INVENTOR(S):            Norman, Mark H., Thousand Oaks, CA, United States
                        Wang, Hui-Ling, Thousand Oaks, CA, United States
                        Rzasa, Robert, Ventura, CA, United States
                        Zhong, Wenge, Thousand Oaks, CA, United States
                        Nguyen, Thomas, Thousand Oaks, CA, United States
                        Kaller, Matthew, Ventura, CA, United States
                        Liu, Hu, Brooklyn, NY, United States
PATENT ASSIGNEE(S):     Amgen, Inc., Thousand Oaks, CA, United States (U.S.
                        corporation)

                             NUMBER        KIND    DATE
                        ---------------- ------ --------
PATENT INFORMATION:     US 6822097          B1   20041123
APPLICATION INFO.:      US 2003-360226           20030206  (10)

                              NUMBER         DATE
                        ------------------ --------
PRIORITY INFORMATION:   US 2002-355313P    20020207 (60)           <--
DOCUMENT TYPE:          Utility
FILE SEGMENT:           GRANTED
PRIMARY EXAMINER:       Seaman, D. Margaret
NUMBER OF CLAIMS:       44
EXEMPLARY CLAIM:        1
```

NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 15475
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Selected compounds are effective for treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 578018-20-9P
(preparation of thiazolyl substituted quinolinones for treating cell proliferative disorders, neurol. disorders and apoptosis)
RN 578018-20-9 USPATFULL
CN 2(1H)-Quinolinone, 3-[2-(4-methoxy-3-nitrophenyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



IT 578018-19-6P 578018-24-3P 578018-56-1P
(preparation of thiazolyl substituted quinolinones for treating cell proliferative disorders, neurol. disorders and apoptosis)
RN 578018-19-6 USPATFULL
CN 2(1H)-Quinolinone, 3-[2-(4-methoxyphenyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



RN 578018-24-3 USPATFULL
CN 2(1H)-Quinolinone, 3-[2-(3-amino-4-methoxyphenyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



RN 578018-56-1 USPATFULL
CN Carbamic acid, [4-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-2-thiazolyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L31 ANSWER 2 OF 7 USPATFULL on STN

ACCESSION NUMBER:	2004:190788 USPATFULL
TITLE:	Pyrid-2-one derivatives and methods of use
INVENTOR(S):	Zhong, Wenge, Thousand Oaks, CA, UNITED STATES Norman, Mark Henry, Thousand Oaks, CA, UNITED STATES Kaller, Matthew, Ventura, CA, UNITED STATES Nguyen, Thomas, Thousand Oaks, CA, UNITED STATES Rzasa, Robert Michael, Ventura, CA, UNITED STATES Tegley, Christopher, Thousand Oaks, CA, UNITED STATES Wang, Hui-Ling, Thousand Oaks, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004147561	A1	20040729	
APPLICATION INFO.:	US 2003-736289	A1	20031212	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-436787P	20021227 (60)	<--

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	AMGEN INC., U.S. Patent Operations/JWB, Dept. 4300, M/S 27-4-A, One Amgen Center Drive, Thousand Oaks, CA, 91320-1799
NUMBER OF CLAIMS:	39
EXEMPLARY CLAIM:	1
LINE COUNT:	7376

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Selected compounds are effective for treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 727382-50-5P, Ethyl 2-ethyl-6-oxo-5-[2-(benzodioxol-5-yl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-96-9P, Ethyl 5-[2-(2H-benzo[d]-1,3-dioxolan-5-yl)-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727382-97-0P, Ethyl 2-methyl-6-oxo-5-(2-phenyl-1,3-thiazol-4-yl)-1,6-dihydro-3-pyridinecarboxylate 727382-98-1P, Ethyl 2-methyl-6-oxo-5-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate

727382-99-2P, Ethyl 5-[2-(2,6-dichlorophenyl)-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-06-4P, Ethyl 2-methyl-6-oxo-5-[2-(4-methoxyphenyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate
(Cdk2/Cdk5 inhibitor; preparation of quinazolines as Cdk2 and Cdk5 kinase inhibitors for treatment of cell proliferation-related disorders)

RN 727382-50-5 USPATFULL
CN 3-Pyridinecarboxylic acid, 5-[2-(1,3-benzodioxol-5-yl)-4-thiazolyl]-2-ethyl-1,6-dihydro-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 727382-96-9 USPATFULL
CN 3-Pyridinecarboxylic acid, 5-[2-(1,3-benzodioxol-5-yl)-4-thiazolyl]-1,6-dihydro-2-methyl-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 727382-97-0 USPATFULL
CN 3-Pyridinecarboxylic acid, 1,6-dihydro-2-methyl-6-oxo-5-(2-phenyl-4-thiazolyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 727382-98-1 USPATFULL
CN 3-Pyridinecarboxylic acid, 5-[2-(4-fluorophenyl)-4-thiazolyl]-1,6-dihydro-2-methyl-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 727382-99-2 USPATFULL
CN 3-Pyridinecarboxylic acid, 5-[2-(2,6-dichlorophenyl)-4-thiazolyl]-1,6-dihydro-2-methyl-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 727383-06-4 USPATFULL
CN 3-Pyridinecarboxylic acid, 1,6-dihydro-5-[2-(4-methoxyphenyl)-4-thiazolyl]-2-methyl-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)



L31 ANSWER 3 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2004:19488 USPATFULL
TITLE: Agent for inhibition of cytokine production and agent for inhibition of cell adhesion
INVENTOR(S): Chihiro, Masatoshi, Naruto-shi, JAPAN
Matsuzaki, TakayukI, Tokushima-shi, JAPAN
Nagamoto, Hisashi, Suita-shi, JAPAN
Miyakoda, Goro, Itano-gun, JAPAN
Sueyoshi, Shinobu, Belmont, CA, UNITED STATES
Mori, Toyoki, Naruto-shi, JAPAN
Kitano, Kazuyoshi, Naruto-shi, JAPAN

Takemura, Isao, Tokyo, JAPAN
Yamashita, Hiroshi, Itano-gun, JAPAN
Tabusa, Fujio, Itano-gun, JAPAN
PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co. Ltd. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014792	A1	20040122
APPLICATION INFO.:	US 2003-424904	A1	20030429 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-887143, filed on 25 Jun 2001, GRANTED, Pat. No. US 6583163 Division of Ser. No. US 1999-269481, filed on 29 Mar 1999, GRANTED, Pat. No. US 6291487 A 371 of International Ser. No. WO 1997-JP3466, filed on 29 Sep 1997, UNKNOWN

	NUMBER	DATE	
PRIORITY INFORMATION:	JP 1996-258533	19960930	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 1300 I STREET, NW, WASHINGTON, DC, 20005
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 1269
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides an agent for inhibiting cytokine production or cell adhesion, comprising at least one compound selected from the group consisting of thiazole derivatives represented by the following general formula: ##STR1##

[wherein R.sup.1 is a phenyl group which may have a lower alkoxy group(s) as a substituent(s) on the phenyl ring, and R.sup.2 is a group represented by the following general formula: ##STR2##

(wherein R.sup.3's, which may be the same or different, are each a carboxyl group, a lower alkoxy group or the like) or the like] and salts thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 145739-56-6P 145740-22-3P 205995-53-5P
(thiazoles for inhibition of cytokine production and cell adhesion)
RN 145739-56-6 USPATFULL
CN 2-Pyridinecarboxylic acid, 6-[2-(3,4-diethoxyphenyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



RN 145740-22-3 USPATFULL
CN 4-Pyridinecarboxylic acid, 2-[2-(3,4-diethoxyphenyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



RN 205995-53-5 USPATFULL
CN 2-Pyridinecarboxylic acid, 4-[2-(3,4-diethoxyphenyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 4 OF 7 USPATFULL on STN

ACCESSION NUMBER:	2002:22633 USPATFULL
TITLE:	Agent for inhibition of cytokine production and agent for inhibition of cell adhesion
INVENTOR(S):	Chihiro, Masatoshi, Tokushima, JAPAN Matsuzaki, Takayuki, Tokushima, JAPAN Nagamoto, Hisashi, Osaka, JAPAN Miyakoda, Goro, Tokushima, JAPAN Sueyoshi, Shinobu, Belmont, CA, UNITED STATES Mori, Toyoki, Tokushima, JAPAN Kitano, Kazuyoshi, Tokushima, JAPAN Takemura, Isao, Tokyo, JAPAN Yamashita, Hiroshi, Tokushima, JAPAN Kurimura, Muneaki, Tokushima, JAPAN Tabusa, Fujio, Tokushima, JAPAN
PATENT ASSIGNEE(S):	Otsuka Pharmaceutical Co., Ltd. (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002013469	A1	20020131	<--
	US 6583163	B2	20030624	
APPLICATION INFO.:	US 2001-887143	A1	20010625 (9)	

RELATED APPLN. INFO.:	Division of Ser. No. US 1999-269481, filed on 29 Mar 1999, GRANTED, Pat. No. US 6291487 A 371 of International Ser. No. WO 1997-JP3466, filed on 29 Sep 1997, UNKNOWN

	NUMBER	DATE	
PRIORITY INFORMATION:	JP 1996-258533	19960930	<--

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	FINNEGAN, HENDERSON, FARABOW, GARRETT &, DUNNER LLP, 1300 I STREET, NW, WASHINGTON, DC, 20005
NUMBER OF CLAIMS:	18
EXEMPLARY CLAIM:	1

LINE COUNT: 1265
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides an agent for inhibiting cytokine production or cell adhesion, comprising at least one compound selected from the group consisting of thiazole derivatives represented by the following general formula: ##STR1##

[wherein R.sup.1 is a phenyl group which may have a lower alkoxy group(s) as a substituent(s) on the phenyl ring, and R.sup.2 is a group represented by the following general formula: ##STR2##

(wherein R.sup.3's, which may be the same or different, are each a carboxyl group, a lower alkoxy group or the like) or the like] and salts thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 145739-56-6P 145740-22-3P 205995-53-5P
(thiazoles for inhibition of cytokine production and cell adhesion)
RN 145739-56-6 USPATFULL
CN 2-Pyridinecarboxylic acid, 6-[2-(3,4-diethoxyphenyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



RN 145740-22-3 USPATFULL
CN 4-Pyridinecarboxylic acid, 2-[2-(3,4-diethoxyphenyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



RN 205995-53-5 USPATFULL
CN 2-Pyridinecarboxylic acid, 4-[2-(3,4-diethoxyphenyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 5 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2001:158310 USPATFULL
TITLE: Agent for inhibition of cytokine production and agent for inhibition of cell adhesion
INVENTOR(S): Chihiro, Masatoshi, Naruto, Japan
Matsuzaki, Takayuki, Tokushima, Japan
Nagamoto, Hisashi, Suita, Japan
Miyakoda, Goro, Itano-gun, Japan
Sueyoshi, Shinobu, Belmont, CA, United States
Mori, Toyoki, Naruto, Japan
Kitano, Kazuyoshi, Naruto, Japan
Takemura, Isao, Tokyo, Japan
Yamashita, Hiroshi, Itano-gun, Japan
Kurimura, Muneaki, Naruto, Japan
Tabusa, Fujio, Itano-gun, Japan
PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE		
PATENT INFORMATION:	US 6291487	B1	20010918		<--
	WO 9814191		19980409		<--
APPLICATION INFO.:	US 1999-269481		19990329	(9)	
	WO 1997-JP3466		19970929		
			19990329	PCT 371 date	
			19990329	PCT 102(e) date	

	NUMBER	DATE	
PRIORITY INFORMATION:	JP 1996-258533	19960930	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Fan, Jane
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 1140
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides an agent for inhibiting cytokine production or cell adhesion, comprising at least one compound selected from the group consisting of thiazole derivatives represented by the following general formula: ##STR1##

[wherein R.sup.1 is a phenyl group which may have a lower alkoxy group(s) as a substituent(s) on the phenyl ring, and R.sup.2 is a group represented by the following general formula: ##STR2##

[wherein R.sup.3 's, which may be the same or different, are each a carboxyl group, a lower alkoxy group or the like) or the like] and salts thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 145739-56-6P 145740-22-3P 205995-53-5P
(thiazoles for inhibition of cytokine production and cell adhesion)
RN 145739-56-6 USPATFULL
CN 2-Pyridinecarboxylic acid, 6-[2-(3,4-diethoxyphenyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



RN 145740-22-3 USPATFULL
CN 4-Pyridinecarboxylic acid, 2-[2-(3,4-diethoxyphenyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



RN 205995-53-5 USPATFULL
CN 2-Pyridinecarboxylic acid, 4-[2-(3,4-diethoxyphenyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 6 OF 7 USPATFULL on STN

ACCESSION NUMBER:	2000:1891 USPATFULL
TITLE:	Thiazole benzenesulfonamides as β3 agonists for treatment of diabetes and obesity
INVENTOR(S):	Mathvink, Robert J., Red Bank, NJ, United States Parmee, Emma R., Highland Park, NJ, United States Tolman, Samuel, Jersey City, NJ, United States Weber, Ann E., Scotch Plains, NJ, United States
PATENT ASSIGNEE(S):	Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6011048		20000104	<--
APPLICATION INFO.:	US 1998-7363		19980115 (9)	

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1997-36760P	19970128 (60)	<--

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Fan, Jane

LEGAL REPRESENTATIVE: Yang, Mollie M., Rose, David L.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 1510
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Thiazole substituted benzenesulfonamides are β.sub.3 adrenergic receptor agonists with very little β.sub.1 and β.sub.2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent activity in the treatment of Type II diabetes and obesity. The compounds can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compounds can be used to reduced neurogenic inflammation or as antidepressant agents. The compounds are prepared by coupling an aminoalkylphenyl-sulfonamide with an appropriately substituted epoxide. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for decreasing gut motility are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 211031-09-3P 211031-35-5P 211032-23-4P
211032-49-4P
(preparation of thiazole benzenesulfonamides as β3 agonists)
RN 211031-09-3 USPATFULL
CN Benzenesulfonamide, N-[4-[2-[[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-(3-pyridinyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 211031-35-5 USPATFULL
CN Benzenesulfonamide, N-[4-[2-[[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-(3-quinolinyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 211032-23-4 USPATFULL
CN Benzenesulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-(3-pyridinyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 211032-49-4 USPATFULL
CN Benzenesulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-(3-quinolinyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





L31 ANSWER 7 OF 7 USPATFULL on STN

ACCESSION NUMBER:	94:24330 USPATFULL			
TITLE:	Thiazolylbenzofuran derivatives and pharmaceutical composition comprising the same			
INVENTOR(S):	Matsuo, Masaaki, Toyonaka, Japan Okumura, Kazuo, Osaka, Japan Shigenaga, Shinji, Kobe, Japan Matsuda, Hiroshi, Osaka, Japan			
PATENT ASSIGNEE(S):	Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5296495		19940322	<--
APPLICATION INFO.:	US 1992-929751		19920812	(7)
	NUMBER		DATE	
PRIORITY INFORMATION:	GB 1991-17733		19910816	<--
	GB 1992-1057		19920117	<--
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Lee, Mary C.			
ASSISTANT EXAMINER:	Haley, Jacqueline			
LEGAL REPRESENTATIVE:	Oblon, Spivak, McClelland, Maier & Neustadt			
NUMBER OF CLAIMS:	8			
EXEMPLARY CLAIM:	1			
LINE COUNT:	2802			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formula: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, A, X and Y are as defined and pharmaceutically acceptable salts thereof; which have activities as leukotriene and Slow Reacting Substance of Anaphalaxis (SRS-a) antagonists or inhibitors, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to methods of using the same therapeutically in the prevention and/or treatment of allergy or inflamation in human beings or animals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 149413-78-5P
(preparation of, as drug)

RN 149413-78-5 USPATFULL

CN Pyridine, 2-[2-[2-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]-5-benzofuranyl]-4-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)


H
N
N
N
N
CH2
O
O
CH2
N
N
S
HCl